October 8, 2012
U.S. FDA Approves the Dexcom G4™ PLATINUM Continuous Glucose Monitor (CGM)
New Device for Diabetes Management is Most-Advanced CGM Available with up to 30% Improvement in Hypoglycemic Accuracy
SAN DIEGO--(BUSINESS WIRE)-- Dexcom(NASDAQ: DXCM), a leader in continuous glucose monitoring, announced today that the U.S. Food and Drug Administrationhas approved its eagerly anticipated new continuous glucose monitoring system, the Dexcom G4™ PLATINUM.
Clinical trials report up to approximately 19 percent improvement in overall accuracy for the Dexcom G4 PLATINUM compared to the Seven Plus, and approximately a 30 percent improvement in accuracy in the hypoglycemia range (i.e., when blood glucose is less than 70mg/dl). The overall accuracy and ease of use for the Dexcom G4 PLATINUM sets a new standard for commercially available CGMs, making the Dexcom G4 PLATINUM the most-advanced CGM system available.
Fulll press release: